Blood Safety

Northfield Laboratories reports preliminary top-line data in pivotal Phase III trauma study

Published in Lab Business Week, January 21st, 2007

Northfield Laboratories Inc. (NFLD) announced preliminary top-line results from its pivotal Phase III trial assessing the safety and efficacy of PolyHeme, its human hemoglobin based oxygen-carrying red blood cell substitute in the treatment of severely injured and bleeding patients when blood is needed but not immediately available.

However, because of discrepancies in the initial data, the database will be unlocked and corrected before finalizing the statistical analyses.

Northfield received the initial draft top-line data from its contract research organization (CRO) on December 14, 2006. During its review and interpretation of these results, two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2007-01-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry